Market Research Report
North America Sleep Apnea Diagnostic and Therapeutic Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||802172|
|Published||Content info||80 Pages
Delivery time: 2-3 business days
|North America Sleep Apnea Diagnostic and Therapeutic Market Forecast 2019-2027|
|Published: March 9, 2019||Content info: 80 Pages||
The rise in the number of incidences of sleep apnea and lack of patient awareness regarding the disease in this region majorly drive the growth of the market in North America. The regional market for sleep apnea diagnostic and therapeutic services are expected to proliferate at a CAGR of 6.00% during the forecasting years of 2019-2027.
The key contributing economies for the North American sleep apnea diagnostic and therapeutic market belongs to the United States and Canada.
According to the estimates published by the Public Health Agency of Canada, 2016, the respiratory diseases account for nearly XX% of the total healthcare costs. Furthermore, more than X million people are expected to suffer from at least one of the major respiratory diseases such as COPD, lung cancer, cystic fibrosis, and asthma. These factors are expected to contribute to market growth in Canada.
The innovation of technologically advanced novel devices to diagnose and treat the patients drives the growth of sleep apnea devices market. The industry players are investing in developing easy-to-use and compact devices for sleep apnea patients.
The established companies that are operating in the North American region are Braebon Medical Corporation, Somnomedics, Medtronic PLC, Invacare Corp., Teleflex, CareFusion (Merged With Becton Dickinson), Nihon Kohden Corporation, Resmed Inc., Drive Devilbiss Healthcare, Cadwell, Koninklijke Philips N.V. (Philips), GE Healthcare, Smiths Group PLC (Smiths Medical), Fisher & Paykel Healthcare, and Itamar Medical Ltd.